240 related articles for article (PubMed ID: 28672816)
1. Augmented Anticancer Effects of Cantharidin with Liposomal Encapsulation: In Vitro and In Vivo Evaluation.
Zhang X; Lin CC; Chan WK; Liu KL; Yang ZJ; Zhang HQ
Molecules; 2017 Jun; 22(7):. PubMed ID: 28672816
[TBL] [Abstract][Full Text] [Related]
2. Liposome encapsulation reduces cantharidin toxicity.
Chang CC; Liu DZ; Lin SY; Liang HJ; Hou WC; Huang WJ; Chang CH; Ho FM; Liang YC
Food Chem Toxicol; 2008 Sep; 46(9):3116-21. PubMed ID: 18652872
[TBL] [Abstract][Full Text] [Related]
3. Cantharidin inhibits cell proliferation and induces apoptosis through G2/M phase cell cycle arrest in hepatocellular carcinoma stem cells.
Le AP; Zhang LL; Liu W; Shi YF
Oncol Rep; 2016 May; 35(5):2970-6. PubMed ID: 26986084
[TBL] [Abstract][Full Text] [Related]
4. Dual-Functional Liposomes with Carbonic Anhydrase IX Antibody and BR2 Peptide Modification Effectively Improve Intracellular Delivery of Cantharidin to Treat Orthotopic Hepatocellular Carcinoma Mice.
Zhang X; Lin C; Chan W; Liu K; Lu A; Lin G; Hu R; Shi H; Zhang H; Yang Z
Molecules; 2019 Sep; 24(18):. PubMed ID: 31547459
[TBL] [Abstract][Full Text] [Related]
5. Development of 11-DGA-3-
Zhou L; Zou M; Zhu K; Ning S; Xia X
Molecules; 2019 Aug; 24(17):. PubMed ID: 31450608
[TBL] [Abstract][Full Text] [Related]
6. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
[TBL] [Abstract][Full Text] [Related]
7. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Xu Y; Wang M; Ning S; Yang Z; Zhou L; Xia X
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296377
[TBL] [Abstract][Full Text] [Related]
8. Optimizing manufacture of liposomal berberine with evaluation of its antihepatoma effects in a murine xenograft model.
Lin YC; Kuo JY; Hsu CC; Tsai WC; Li WC; Yu MC; Wen HW
Int J Pharm; 2013 Jan; 441(1-2):381-8. PubMed ID: 23220078
[TBL] [Abstract][Full Text] [Related]
9. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
10. Cantharidin induces G2/M arrest and triggers apoptosis in renal cell carcinoma.
Ren Y; Zhang SW; Xie ZH; Xu XM; Chen LL; Lou ZG; Weng GB; Yao XP
Mol Med Rep; 2016 Dec; 14(6):5614-5618. PubMed ID: 27878266
[TBL] [Abstract][Full Text] [Related]
11. Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells.
Liu W; Ning R; Chen RN; Huang XF; Dai QS; Hu JH; Wang YW; Wu LL; Xiong J; Hu G; Guo QL; Yang J; Wang H
Mol Carcinog; 2016 May; 55(5):440-57. PubMed ID: 25683703
[TBL] [Abstract][Full Text] [Related]
12. SC-III3, a novel scopoletin derivative, induces cytotoxicity in hepatocellular cancer cells through oxidative DNA damage and ataxia telangiectasia-mutated nuclear protein kinase activation.
Zhao P; Chen L; Li LH; Wei ZF; Tong B; Jia YG; Kong LY; Xia YF; Dai Y
BMC Cancer; 2014 Dec; 14():987. PubMed ID: 25527123
[TBL] [Abstract][Full Text] [Related]
13. GL-V9, a newly synthetic flavonoid derivative, induces mitochondrial-mediated apoptosis and G2/M cell cycle arrest in human hepatocellular carcinoma HepG2 cells.
Li L; Lu N; Dai Q; Wei L; Zhao Q; Li Z; He Q; Dai Y; Guo Q
Eur J Pharmacol; 2011 Nov; 670(1):13-21. PubMed ID: 21944925
[TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Vivo Evaluation of SP94 Modified Liposomes Loaded with N-14NCTDA, a Norcantharimide Derivative for Hepatocellular Carcinoma-Targeting.
Jiang Y; Liu X; Tan X; Hou Y; Sun W; Gou J; Yin T; He H; Zhang Y; Tang X
AAPS PharmSciTech; 2020 Oct; 21(7):277. PubMed ID: 33033942
[TBL] [Abstract][Full Text] [Related]
15. Honokiol nanoparticles based on epigallocatechin gallate functionalized chitin to enhance therapeutic effects against liver cancer.
Tang P; Sun Q; Yang H; Tang B; Pu H; Li H
Int J Pharm; 2018 Jul; 545(1-2):74-83. PubMed ID: 29715531
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.
Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C
Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
[TBL] [Abstract][Full Text] [Related]
18. Effect of a controlled-release drug delivery system made of oleanolic acid formulated into multivesicular liposomes on hepatocellular carcinoma in vitro and in vivo.
Luo Y; Liu Z; Zhang X; Huang J; Yu X; Li J; Xiong D; Sun X; Zhong Z
Int J Nanomedicine; 2016; 11():3111-29. PubMed ID: 27471381
[TBL] [Abstract][Full Text] [Related]
19. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
[TBL] [Abstract][Full Text] [Related]
20. Use of different ligand modification liposomes to evaluate the anti-liver tumor activity of cantharidin.
Zou M; Xu Y; Lin P; Zhou L; Xia X
J Liposome Res; 2023 Sep; 33(3):283-299. PubMed ID: 36594207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
